drugset
drugset / Trial / NCT03937648

Study to Evaluate Pharmacokinetics, Safety, and Tolerability Ildong COL-144 Tablet in Korean Healthy Volunteers

NCT03937648 ↗

Phase 1 Unknown 64 enrolled IlDong Pharmaceutical Co Ltd
RandomizedSequentialDouble-blindTreatment

Summary

A Randomized, Double blind, Placebo-controlled, Single-dose, Dose-escalation Study to Evaluate Pharmacokinetics, Safety, and Tolerability with Oral Administration of Ildong COL-144 tablet in Korean Healthy Volunteers

Timeline

Start
2019-08-01
Primary completion
2019-10-31
Completion
2019-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Lasmiditan Small molecule 50 mg Oral
Subject Lasmiditan Small molecule 100 mg Oral
Subject Lasmiditan Small molecule 200 mg Oral
Subject Lasmiditan Small molecule 400 mg Oral

Indications

No indication recorded.